[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mg---myasthenia-gravis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mg---myasthenia-gravis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644739","phase-2-adapt-forward-2---isa2---a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-empasiprubart-iv-monotherapy-in-participants-with-achr-ab-seropositive-generalized-myasthenia-gravis-100644739",false,"NCT07673627","ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis","ISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis","ADAPT Forward2","Inclusion Criteria:\n\n* Is seropositive for anti-acetylcholine receptor antibodies (AChR-Ab).\n* Has confirmed diagnosis of gMG and is Myasthenia Gravis Foundation of America (MGFA) Class II, III, IVa, or IVb.\n* Has documented immunization against encapsulated bacterial pathogens (Neisseria meningitidis and Streptococcus pneumoniae) within 5 years before ISA screening or will complete immunization at least 14 days before the first IMP administration.\n\nExclusion Criteria:\n\n* Clinical diagnosis of systemic lupus erythematosus (SLE).\n* Is receiving concurrent complement inhibitors (eg, eculizumab, zilucoplan, ravulizumab, or others). Participants who received zilucoplan or eculizumab \\>2 months or ravulizumab \\>6 months before baseline are allowed to participate.\n* Has received an FcRn antagonist, including efgartigimod, within 4 weeks before baseline.\n* Had prior empasiprubart exposure.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.\n\nThe aim of this ISA2 is to investigate the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG).\n\nThe ADAPT Forward master protocol is registered on https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT07294170\n\nMore information can be found here: https:\u002F\u002Fclinicaltrials.argenx.com\u002Fadaptforward2",[27,28,29,30],"AChR-Ab Seropositive Generalized Myasthenia Gravis","Myasthenia Gravis (MG)","MG - Myasthenia Gravis","gMG","RECRUITING","2026-08-20",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":35},"2026-07-10",{"date":39,"type":21},"2028-04",{"name":41,"class":42},"argenx","INDUSTRY",3,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":70,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100651499","the-axis-registry-is-a-10-year-longitudinal-research-initiative-that-captures-the-real-world-experiences-of-people-living-with-autoimmune-neurology-conditions-launching-in-myasthenia-gravis-mg-we-plan-to-evaluate-expansion-to-other-conditions-across-autoimmune-neurology-100651499","NCT07761026","AXIS MG Patient Registry","AXIS Autoimmune Neurology Registry","AXIS","Inclusion Criteria:\n\n* Physician-confirmed diagnosis of myasthenia gravis (MG)\n* Willing and legally able to provide consent\n* Lives in the United States\n\nExclusion Criteria:\n\n* Unwilling or unable to provide consent or comprehend and complete questionnaires\n* Cognitively impaired adults\u002Funable to comprehend or understand the consent or overall study information",{"count":53,"type":21},1000,"10 Years","OBSERVATIONAL","The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.\n\nThe main questions the registry aims to answer are:\n\n* How do symptoms, daily functioning, and quality of life change over time?\n* What treatments do participants use, and how are these treatments related to their symptoms and health?\n* What challenges do participants experience with treatment, including side effects, treatment burden, missed doses, and access to care?\n\nParticipants will:\n\n* Join the registry and complete an enrollment survey (online or through a mobile app)\n* Complete a brief online survey about their MG approximately once a month\n* Provide information that can help confirm their MG diagnosis\n* Optionally, share their medical records with the research team\n\nThis is an observational study. The registry will not assign treatments or ask participants to change their medical care. Information collected through the registry may help researchers better understand MG and improve future research and care.",[28,58,59,60,61,62,63,64,65,66,67,68,27,69,29],"Myasthenia Gravis, Generalized","Myasthenia Gravis, Ocular","Myasthenia Gravis Crisis","Myasthenia Gravis Associated With Thymoma","Myasthenia Gravis Exacerbations","Myasthenia Gravis Generalised","Myasthenia Gravis Generalized","Myasthenia Gravis, Thymectomy","Myasthenia Gravis","Myasthenia Gravis, MuSK","AChR Myasthenia Gravis","MG",[71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86],"myasthenia gravis","autoimmune diseases of the nervous system","neuromuscular junction diseases","patient registries","natural history","longitudinal studies","observational study","patient-reported outcome measures","quality of life","activities of daily living","treatment patterns","medication adherence","treatment burden","healthcare utilization","disease progression","real-world data","2026-08-14",{"date":89,"type":35},"2026-08-17",{"date":91,"type":35},"2026-03-19",{"date":93,"type":21},"2036-03",{"name":95,"class":96},"Autoimmune Neurology Alliance","OTHER",1]